چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Understanding the molecular mechanisms of cancer biology introduces targeted therapy as a complementary method along with other conventional therapies. Recombinant immunotoxins are tumor specific antibodies that their recognizing fragment is utilized for delivering modified toxins into tumor cells. These molecules have been con‑ sidered as a targeted strategy in the treatment of human cancers. HER2 tumor biomarker is a transmembrane tyrosine kinase receptor that can be used for targeted therapies in the forms of anti‑HER2 monoclonal antibodies, antibody– drug conjugates and immunotoxins. There have been many studies on HER2‑based immunotoxins in recent years, however, little progress has been made in the clinical field which demanded more improvements. Here, we summa‑ rized the HER2 signaling and it’s targeting using immunotherapeutic agents in human cancers. Then, we specifically reviewed anti‑HER2 immunotoxins, and their strengths and drawbacks to highlight their promising clinical impact |
| نویسنده | نفر چندم مقاله |
|---|---|
| رضا محمودی | اول |
| حسن دیانت مقدم | دوم |
| سمانه سیاپوش | چهارم |
| وحدت پورطهماسبی | پنجم |
| محمد رحمتی | هفتم |
| رضا صلاحلو | ششم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Paper 1.pdf | 1400/06/16 | 1452724 | دانلود |
